CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.965
+0.155 (3.22%)
Mar 4, 2026, 2:37 PM EST - Market open
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 8.86, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 78.45% from the current stock price of 4.97.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $6 → $10 | Buy | Maintains | $6 → $10 | +101.41% | Feb 4, 2026 |
| Barclays | Barclays | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +101.41% | Feb 4, 2026 |
| Barclays | Barclays | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +61.13% | Jan 20, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +101.41% | Jan 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $6.5 → $10 | Buy | Maintains | $6.5 → $10 | +101.41% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
85.15M
from 138.10M
Decreased by -38.34%
Revenue Next Year
31.87M
from 85.15M
Decreased by -62.57%
EPS This Year
-0.03
from 0.38
EPS Next Year
-0.39
from -0.03
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 95.1M | 84.0M | ||||
| Avg | 85.2M | 31.9M | ||||
| Low | 77.9M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -31.2% | -1.4% | ||||
| Avg | -38.3% | -62.6% | ||||
| Low | -43.6% | -95.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.02 | -0.22 | ||||
| Avg | -0.03 | -0.39 | ||||
| Low | -0.06 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -94.4% | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.